Reducing Children's Racial Biases Via a Parent-Led Intervention

June 9, 2026 updated by: University of Wisconsin, Madison
The goal of this clinical trial is to test a parent-led program for reducing children's racial biases in White families. The main question it aims to answer is: With training, can parents effectively address their children's racial biases? Parent will receive training and tools for addressing their children's racial biases. Researchers will study effects on both parents' and children's racial biases.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
704

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • United States
    • Wisconsin
      • Madison, Wisconsin, United States, 53705
        • Waisman Center at UW-Madison

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

5 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • The child is 5.00 to 7.99 years of age
  • The child participant and their parent are both non-Hispanic White

Exclusion criteria are:

  • Non-proficiency in English on the part of the parent or the child
  • The parent is <18 years old
  • The child or parent identifies with another racial/ethnic identity in addition to White

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: EmBARK
Parents receive a narrated training program about children's racial biases and read books that are focused on race with their children.
Behavioral: EmBARK
The narrated training teaches parents about children's biases and introduces multiple strategies for addressing children's biases. Families receive children's books to help practice the strategies.
Experimental: Popular guidance
Parents receive interesting popular press articles about children's racial biases and read books that are focused on race with their children.
Behavioral: Popular guidance
The popular press articles teach parents about children's biases and guide parents about how to talk to children about race. Families receive children's books focused on race to help practice talking about race.
Experimental: Practice first
Parents practice discussing books about animals with their children first, and then receive a narrated training program about children's racial biases and read books that are focused on race with their children.
Behavioral: Practice first
Animal books are provided to parents to help them practice talking to their children when reading books. Then, families receive a training program about race as well as children's books about race.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Likelihood of Child's Racial Bias
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores from 1-5. Higher scores mean higher likelihood of bias.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Concern about Children's Racial Bias
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores from 1-10. Higher scores indicate more concern.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Concern about Own Child's Bias
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores from 1-10. Higher scores indicate more concern.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Motivation to Regulate Children's Bias
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores from 1-10. Higher scores mean greater motivation.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Self-Efficacy for Addressing Children's Bias
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores from 1-7. Higher scores mean greater self-efficacy.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Intergroup Liking
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores is -12 to +12. Higher scores reflect more ingroup liking.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Diversity Preference
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores is 0 to 4. Higher scores mean a greater preference for homogeneous groups.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Reactions to Discrimination: Evaluation
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores is -6 to +6.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Reactions to Discrimination: Confrontation
Time Frame: Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Participants can score 0 or 1, with the higher score reflecting confrontation.
Baseline, Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Change in Predicting Parents' Attitudes
Time Frame: Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)
Total possible range of scores is -6 to +6.
Post-Test 1 (up to 4 weeks on study), Post-Test 2 (up to 16 weeks on study)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Wisconsin, Madison

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 25, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 15, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 29, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 29, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 10, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 9, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2020-1026
  • 1R01HD106970-01A1 (U.S. NIH Grant/Contract)
  • Psychology (Other Identifier: UW Madison)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data collected during the trial, after de-identification, will be shared. Additionally, the study protocol, statistical analysis plan, informed consent form, and analytic code will be shared. The materials will be shared upon publication of primary outcomes, and will be available indefinitely. They will be shared via an open science platform, namely the Open Science Framework (OSF). Anyone may access the data to verify study outcomes or make additional data discoveries.

IPD Sharing Time Frame

The materials will be shared upon publication of primary outcomes, and will be available indefinitely.

IPD Sharing Access Criteria

The data will be shared via an open science platform, namely the Open Science Framework (OSF). Anyone may access the data to verify study outcomes or make additional data discoveries.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings